Ten neurotic outpatients (five men, five women) received up to 75 hours of psychotherapy over 2 to 6 months, with 3,4-methylenedioxyamphetamine (MDA) administered as an adjunct in two to four sessions. The drug was well tolerated with no serious side effects. Pre- and post-treatment psychometric assessments, including the MMPI, Wittenborn Psychiatric Rating Scales, and Brief Psychiatric Rating Scale, showed significant reductions in depression, anxiety, and obsessive-compulsive traits, along with improvements in well-being and self-actualization. No patient worsened. A 6-month follow-up using the same measures plus a Social History Questionnaire supported these improvements.
A pilot project with thirty cancer patients experiencing psychological distress combined about twelve hours of conventional verbal psychotherapy over four weeks with a single intensive drug-assisted therapy session using dipropyltryptamine (DPT), a short-acting psychedelic. Analysis of psychological tests and independent ratings before and after the intervention suggests the total therapeutic approach enhances quality of life. The text discusses the relative merits of DPT compared to LSD and the need for a controlled study.
A case report describes the use of psychedelic drugs as an adjunct to psychotherapy for a single patient. The treatment involved administering a psychedelic substance during therapy sessions to facilitate emotional insight and psychological healing. The report details the patient's background, the therapeutic process, and the outcomes observed. The authors suggest that psychedelic-assisted psychotherapy may offer benefits for certain individuals, particularly those who have not responded well to conventional treatments. The case illustrates the potential for these drugs to enhance the therapeutic experience and promote lasting psychological change, though the findings are limited to this single case and cannot be generalized without further research.